Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Aditya Bardia |
| Publication date | May 9, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |